Applied Genetic Technologies (AGTC) Reports Q2 EPS of 17c

Applied Genetic Technologies (NASDAQ: AGTC) reported Q2 EPS of $0.17, may not compare to the analyst estimate of ($0.19). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $8.76 million.

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• SuperCom (SPCB) Tops Q3 EPS by 43c